Quming Powder Veterinary Grade API is a dry, multi-route veterinary active pharmaceutical ingredient supplied for incorporation into tablets, injections, capsules, powders, granules, premixes, and solutions. The product is identified under the designation Quming Powder Veterinary Grade API without an internal model suffix; where a particular particle-size variant is required, the difference is recorded on the certificate of analysis as the lot-specific particle-size distribution and not as a separate finished-product code. This keeps the regulatory identity stable while allowing processing variants to be controlled through release testing.

Release control is designed for pharmaceutical use rather than feed-grade use. The active ingredient is tested against a registered specification that includes identity, assay, related substances, water content, residual solvents, elemental impurities, microbial quality, and particle-size characteristics. Each batch is supported by a certificate of analysis and, where the downstream use includes parenteral preparation, by a bacterial endotoxin result generated in accordance with Ph. Eur. 2.6.14. The multi-route designation means that a single batch may be qualified for oral and parenteral finished-product development only if the more restrictive injectable-grade controls are met; otherwise the batch is limited to non-parenteral use. Because no pharmacopoeial monograph specific to Quming Powder Veterinary Grade API is publicly available, the release specification is derived from the registered veterinary medicinal product file and the relevant general chapters. Exact acceptance ranges are batch-specific and must be read from the CoA rather than inferred from this technical introduction.

Which Control Parameters Separate This Grade from Technical-Grade and Feed-Grade Powders?

The primary difference is not the chemical identity of the active substance but the control burden applied to the powder. A veterinary API grade must satisfy pharmaceutical control requirements for residual solvents under VICH GL18, elemental impurities under Ph. Eur. 2.4.20 or USP <233>, and microbial limits under Ph. Eur. 5.1.4. A technical-grade powder may be supplied with only a basic assay and water content; a feed-grade premix powder may carry high microbial loads and no pharmacopoeial solvent profile. For Quming Powder Veterinary Grade API, the multi-route designation further requires that the same powder be assessed for particle-size distribution by laser diffraction per ISO 13320:2020, because the powder must function in a tablet direct-compression blend as well as in a solution for sterile filtration. The release specification also addresses bacterial endotoxin for parenteral use, while a pure feed additive specification does not normally include this parameter. These controls make the powder suitable for incorporation into finished veterinary dosage forms but do not make the powder a finished veterinary product.

Release Specification Parameters and Pharmacopoeial Cross-References

The following matrix identifies the control parameters commonly stated on the certificate of analysis for multi-route veterinary API powders and the pharmacopoeial methods used to generate the data. Acceptance limits are not reproduced here because they are filing-specific; the standards give the technical basis for generating compendially acceptable data.

Analytical methods used for release and stability are validated for specificity, linearity, accuracy, precision, and robustness under ICH Q2 or the veterinary equivalent. The assay method is stability-indicating and separates the active peak from process impurities, degradation products, and formulation matrices. For injectable-grade lots, the method is also checked for interference from Water for Injection and rubber closure extractables. If the powder is used in several finished products with different matrices, an additional matrix interference study is performed for each formulation.

Beyond the matrix, batches intended for direct compression are often tested for flow behaviour and compressibility. The powder is sampled after final blending and mounted on a powder flow tester; the angle of repose is measured according to USP <1174>. Bulk and tapped density are measured according to Ph. Eur. 2.9.34 or USP <616>. These data are used to set die fill depth, hopper vibration, and press speed. A multi-route powder that shows acceptable flow for a V-blender may nevertheless require a glidant for high-speed tablet compression, so the release data are not a substitute for formulation-specific trials.

Controlled milling is used to bring the powder into the target particle-size range. Air-jet milling or pin milling under nitrogen reduces the risk of oxidative degradation and amorphous surface generation. Dynamic vapour sorption may be used to characterise moisture uptake at 40 °C and 75% RH; if the powder shows a moisture uptake above the registered limit, processing is conducted below 60% RH and the product is packaged in a double polyethylene liner inside a fibre drum. Particle-size distribution is reported as D10, D50, and D90 by ISO 13320:2020; the D90 for oral direct-compression blends is often maintained at ≤150 µm, while injection-grade material may require a finer distribution if the final solution is prepared without a solubilising step. Published data for this specific configuration are limited, so the exact D values must be taken from the batch CoA.

Direct compression of the powder into veterinary tablets is performed on a rotary tablet press with compaction force monitoring. The formulation is considered suitable for direct compression when the angle of repose remains below 40° and the flow through a standard funnel is sufficient to maintain die-fill consistency; if the angle of repose exceeds 40°, wet granulation or roller compaction is used. Tablet hardness, friability, and disintegration are measured according to Ph. Eur. 2.9.8 and Ph. Eur. 2.9.1. Content uniformity is evaluated according to Ph. Eur. 2.9.5 or USP <905>. Loss-on-drying values are confirmed from the batch certificate because moisture above the registered limit can cause picking, sticking, and variable tablet hardness. In low-dose tablets, segregation is controlled by matching the API particle-size distribution to the filler particle-size distribution; if the API is finer than the filler, the blend may be ordered by dry binder addition or by reducing the hopper fill level.

In-process controls on a tablet line include compaction force, ejection force, and punch displacement. When the ejection force exceeds the limit defined during development, the powder may be sticking to the die wall, and lubrication is increased or the moisture content is rechecked. A rotary press with pre-compression is preferred for direct compression because it allows air to escape from the powder bed and reduces capping. Press speed is set from the flow function coefficient; if the powder has a high compressibility index, the press may be operated at a lower speed to maintain weight uniformity.

For capsule filling, the powder is discharged from a dosator or tamping-pin machine. Bulk density and tapped density, measured by Ph. Eur. 2.9.34 or USP <616>, are used to calculate fill volume and to set the target fill weight. Particle-size distribution controls powder bed cohesion; highly cohesive powders may require slugging, dry granulation, or the addition of a glidant. Microbial quality is checked against the non-sterile oral limits of Ph. Eur. 5.1.4, and the same data support the use of the powder in oral powders and granules. Capsule fill weight variation is monitored by Ph. Eur. 2.9.5, and the filling-machine speed is reduced if the powder shows high bulk density variation or static adhesion.

For tablet and capsule finished products, dissolution testing is conducted in a pharmacopoeial apparatus according to Ph. Eur. 2.9.3 or USP <711> where required. The medium is selected from pH-solubility data; if the API is weakly acidic or basic, a two-stage dissolution test in 0.1 M hydrochloric acid followed by a neutral buffer may be used to detect a formulation failure. The API itself may show a particle-size-dependent dissolution rate; fine particles may dissolve more rapidly but may also increase moisture uptake and static charge.

Injectable solutions are prepared by dissolving the powder in Water for Injection, adjusting pH, and passing the solution through a 0.22 µm sterilising-grade membrane filter. The filter is selected for compatibility with the final solvent system because the API may precipitate at the filter surface if the pH is near the solubility boundary. Bacterial endotoxin is controlled at release according to Ph. Eur. 2.6.14; membrane filtration removes microorganisms but does not remove endotoxin. Particulate matter is measured by light obscuration or membrane microscopy using Ph. Eur. 2.9.19. Because the powder is also used in oral forms, the parenteral route is appropriate only for batches that meet the registered endotoxin and sub-visible particle limits; oral-only batches are segregated and labelled accordingly. The powder must also have a low water content and a defined residue on ignition to prevent visible precipitation and filter blocking. For highly concentrated injectable solutions, the maximum concentration is established by equilibrium solubility in the selected vehicle, not by the API assay alone.

For injectable-grade lots, the release file includes the bacterial endotoxin result, a low bioburden count, and in some cases sub-visible particle data for the reconstituted solution. The solution is prepared in Water for Injection and filtered through a 0.22 µm membrane; the filterability test is performed on a small-volume pressure vessel with a constant pressure of 2 bar to 3 bar using a 47 mm disc filter. Filtration time and volume are recorded because adsorption or precipitation can reduce filter capacity. This test is not required for oral powders or premixes, but it is relevant when the same API is listed for injectable solutions.

Powders and granules for oral administration are manufactured in low-shear V-blenders, bin blenders, or ribbon blenders. Mixing uniformity is demonstrated by sampling at the top, middle, and bottom of the blender and assay by a validated HPLC method. For premixes, the API is blended with a feed carrier in a separate facility or a dedicated area; the API itself is not a finished premix and is not added directly to feed without an authorised dilution step. The difference from a feed-grade powder is that residual solvent and degradation profiles are controlled under VICH GL18 and Ph. Eur. 2.2.46, so solvent or degradation residues are not introduced into the feed chain through the premix. In low-inclusion premixes, geometric dilution is required to prevent segregation; the number of dilution steps is selected from the ratio between the active concentration in the final feed and the limit of detection of the validated assay.

For oral solutions, the powder is dissolved in a purified or buffered vehicle. The release specification does not establish solubility; solubility is a function of the final vehicle pH, ionic strength, and co-solvent content. A pH-solubility profile is generated in pharmacopoeial buffer systems, and a short-term forced-degradation study is used to confirm that the solution remains within the registered related-substances limit over the intended in-use period. If the API shows oxidative sensitivity, nitrogen purging and light-resistant packaging are evaluated during finished-product development; the dry powder may be more stable than the solution, so the solution is prepared close to the point of use unless stability data support extended storage.

Water activity is not a batch release parameter for every lot, but it is measured during development when the powder is used in moisture-sensitive formulations. A water activity below 0.60 generally reduces microbial growth risk; however, the actual limit is set by the finished-product stability data and the registered specification. If the powder is stored in a climate with high humidity, a desiccant protected by a cotton plug is placed inside the primary container, and the container is sealed immediately after sampling.

When an Approved Formulation Is Switched from Another Veterinary API Source to Quming Powder Veterinary Grade API

Source-to-source substitution is not automatic. The marketing authorisation holder compares impurity profile, residual solvent profile, crystal habit, particle-size distribution, and polymorphic form where relevant. A change in particle-size distribution may alter blend uniformity and dissolution; a change in crystal habit may alter powder flow, compaction behaviour, and filterability. The finished-product dossier should contain a bridging study that includes assay, related substances, content uniformity, dissolution or disintegration where applicable, and moisture uptake under controlled humidity. Stability data may be required under VICH GL3 if the source change alters the degradation rate. The change also triggers revalidation of cleaning procedures because the adhesive properties of the new powder may differ from the previous source.

Stability storage is performed in accordance with the climatic zones described for veterinary products. The powder is packed in a vapour-tight container and stored at controlled room temperature; if the product is intended for tropical markets, long-term storage at 30 °C and 65% RH may be required under VICH GL3. The retest interval is assigned from long-term data, not from accelerated data alone. Open-container stability should be assessed if the powder is exposed repeatedly during batching; if moisture uptake is high, a nitrogen overlay or desiccant is used in the primary package.

Cleaning validation is executed on the actual production train after campaign manufacture. Swab and rinse sampling locations are selected from a residue risk map, and samples are analysed by a validated HPLC method with a limit based on the permitted daily exposure of the next product. For multi-route campaigns, the lowest residue limit among subsequent products is used; this is often the injectable or oral drench product. If the same equipment is used for Quming Powder Veterinary Grade API and other veterinary APIs, a carryover study is performed in the presence of the worst-case following product. Published data for this specific configuration are limited, so equipment-specific recovery factors, residue limits, and sampling recovery studies must be generated during technology transfer.

The powder should not be handled in open air under uncontrolled humidity. Contact surfaces in the milling, blending, and compression equipment are stainless steel or equivalent; bronze or reactive metal components are avoided where the API may be sensitive to metal ions. If a metal-induced degradation pathway is identified, edetate disodium or another chelator is added in the finished formulation rather than accepting the API under a reduced shelf life.